NickDeIuliis
Analyst · Wells Fargo
So, great questions. This is the big capital allocation of the free cash flow issue which we spend just in an ordinate amount of time looking upon and to certain extent obsessing on not just the management team, but also our board. So it's important, right, if it's front and center to sort of one of the two key components of our strategy and what we think makes us special. When you look at what we are sort of faced with here, when it comes to free cash flow allocation into '22. We've got to two issues here. One, we've got a definite desire to continue to strengthen the balance sheet and predominantly right, that correlates to reducing the absolute level of debt. But that also includes and Q4 was a good example of this. This also includes some opportunistic moves, to either reduce our interest expense with a debt that's still in place via refis, right, or to extend out maturities or both. And we did both of those types of things in '22, Q4, I'm sorry, '21, Q4. 7So we'll continue to look for those types of opportunities as well. But really, our primary focus, at least from my perspective, on the balance sheet side is to continue as we said in the past, to methodically reduce the absolute amount of debt through some portion of free cash flow allocation, and we think if nothing else, not only that it reduce interest expense, right and it sort of boost free cash flow into the future, it creates for more optionality to be able to take advantage of volatile spaces, like E&P is and like public markets are. But then two, right, the other thing we're faced with is these, the shares that are basically offering up and we used to talk in the old days of early '21, about high teens free cash flow yields, and now we're looking at 20 plus percent free cash flow yields. And we said we'd like high teen free cash flow yields. So we're going to love right 20 plus percent free cash flow yields. And we want to take advantage of that as well. So right now, it's to a certain extent, I suppose, a bit of a capital allocation Nirvana, where we've got sort of a number of really attractive opportunities. And in '22, I think the plan when it comes to the $600 million, is to sort of allocate that mix between those two that I just outlined, strengthening balance sheet continues on and taken advantage of discounted shares of some pretty juicy free cash flow yield continues on. With respect to dividends, not adverse to dividends, our board and management team understand that can be a very efficient way to get capital returns to shareholders. But once again, we go back to that that clinical approach. Right now the risk adjusted rate of returns a share buybacks are so compelling, what we're doing with respect to free cash flow generation that the dividends for the time being until something changes materially are not the most efficient way to return capital to shareholders or not the best way to create the long- term intrinsic per share value. And I do understand to your point, right, the rest of the industry is talking about doing it that like we sort of pride ourselves on taking a bit of a different approach. So until that math changes, I think it's going to be debt reduction and share count reduction.